213 related articles for article (PubMed ID: 21429575)
1. The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation.
Stachelek SJ; Finley MJ; Alferiev IS; Wang F; Tsai RK; Eckells EC; Tomczyk N; Connolly JM; Discher DE; Eckmann DM; Levy RJ
Biomaterials; 2011 Jul; 32(19):4317-26. PubMed ID: 21429575
[TBL] [Abstract][Full Text] [Related]
2. Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces.
Finley MJ; Rauova L; Alferiev IS; Weisel JW; Levy RJ; Stachelek SJ
Biomaterials; 2012 Aug; 33(24):5803-11. PubMed ID: 22613135
[TBL] [Abstract][Full Text] [Related]
3. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
[TBL] [Abstract][Full Text] [Related]
4. CD47-dependent molecular mechanisms of blood outgrowth endothelial cell attachment on cholesterol-modified polyurethane.
Ueda M; Alferiev IS; Simons SB; Hebbel RP; Levy RJ; Stachelek SJ
Biomaterials; 2010 Sep; 31(25):6394-9. PubMed ID: 20538335
[TBL] [Abstract][Full Text] [Related]
5. Novel structural determinants on SIRP alpha that mediate binding to CD47.
Lee WY; Weber DA; Laur O; Severson EA; McCall I; Jen RP; Chin AC; Wu T; Gernert KM; Parkos CA
J Immunol; 2007 Dec; 179(11):7741-50. PubMed ID: 18025220
[TBL] [Abstract][Full Text] [Related]
6. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
7. CD47-Mediated Hedgehog/SMO/GLI1 Signaling Promotes Mesenchymal Stem Cell Immunomodulation in Mouse Liver Inflammation.
Sheng M; Lin Y; Xu D; Tian Y; Zhan Y; Li C; Farmer DG; Kupiec-Weglinski JW; Ke B
Hepatology; 2021 Sep; 74(3):1560-1577. PubMed ID: 33765345
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
9. CD47 functions as a molecular switch for erythrocyte phagocytosis.
Burger P; Hilarius-Stokman P; de Korte D; van den Berg TK; van Bruggen R
Blood; 2012 Jun; 119(23):5512-21. PubMed ID: 22427202
[TBL] [Abstract][Full Text] [Related]
10. Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol.
Stachelek SJ; Alferiev I; Fulmer J; Ischiropoulos H; Levy RJ
J Biomed Mater Res A; 2007 Sep; 82(4):1004-11. PubMed ID: 17370325
[TBL] [Abstract][Full Text] [Related]
11. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
12. The use of the ex vivo Chandler Loop Apparatus to assess the biocompatibility of modified polymeric blood conduits.
Slee JB; Alferiev IS; Levy RJ; Stachelek SJ
J Vis Exp; 2014 Aug; (90):. PubMed ID: 25178087
[TBL] [Abstract][Full Text] [Related]
13. Intracellular signaling mechanisms associated with CD47 modified surfaces.
Finley MJ; Clark KA; Alferiev IS; Levy RJ; Stachelek SJ
Biomaterials; 2013 Nov; 34(34):8640-9. PubMed ID: 23948164
[TBL] [Abstract][Full Text] [Related]
14. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
15. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
Matozaki T; Murata Y; Okazawa H; Ohnishi H
Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
[TBL] [Abstract][Full Text] [Related]
16. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
[TBL] [Abstract][Full Text] [Related]
17. The hybrid CL-SP-D molecule has the potential to regulate xenogeneic rejection by human neutrophils more efficiently than CD47.
Iemitsu K; Sakai R; Maeda A; Gadomska K; Kogata S; Yasufuku D; Matsui J; Masahata K; Kamiyama M; Eguchi H; Matsumura S; Kakuta Y; Nagashima H; Okuyama H; Miyagawa S
Transpl Immunol; 2024 Jun; 84():102020. PubMed ID: 38452982
[TBL] [Abstract][Full Text] [Related]
18. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47.
Lee WY; Weber DA; Laur O; Stowell SR; McCall I; Andargachew R; Cummings RD; Parkos CA
J Biol Chem; 2010 Dec; 285(49):37953-63. PubMed ID: 20826801
[TBL] [Abstract][Full Text] [Related]
19. Structure of the human marker of self 5-transmembrane receptor CD47.
Fenalti G; Villanueva N; Griffith M; Pagarigan B; Lakkaraju SK; Huang RY; Ladygina N; Sharma A; Mikolon D; Abbasian M; Johnson J; Hadjivassiliou H; Zhu D; Chamberlain PP; Cho H; Hariharan K
Nat Commun; 2021 Sep; 12(1):5218. PubMed ID: 34471125
[TBL] [Abstract][Full Text] [Related]
20. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
